Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions reflect a high level of engagement with the research, as seen in phrases like 'landmark trial,' 'survival benefit,' and 'paving the way for ICDs,' which highlight the importance and influence of the publication. The tone is largely supportive and analytical, emphasizing the significance of the trial's findings for clinical practice and future research.
Most posts clearly support the conclusion that ICD therapy offers a significant survival benefit for patients with congestive heart failure, aligning with the article's findings.
The discussions demonstrate high curiosity, referencing landmark studies like SCD-HeFT and MADIT II, and emphasizing the importance of these treatments.
Many discussions delve into detailed analysis of the trial results, mentioning specific patient groups, methods, and implications, indicating deep engagement.
The overall tone suggests that these findings are perceived as highly impactful, potentially influencing clinical practice and treatment decisions in cardiology.
Two landmark RCTs, MADIT II and SCD-HeFT, have established the concept of ICDs for the primary prevention of SCD in patients with HFrEF by showing a survival benefit with this approach. https://t.co/ZNRkekRxFR https://t.co/thHeU5OHn8 2/x
@rntobsnteach @DrMarthaGulati @TheBJCA @DrRiyazPatel @MrTheProf @DrDavidWarriner @mmamas1973 @Perrycardium @chapdoc1 @drlynnemillar @bcostelloMD @DrChrisMcAloon @DeepDastidar @Dr_DanMD A great landmark trial published in 2005 paving the way for ICDs in severe LV dysfunction https://t.co/ToK4HzgZu2 - thanks for choosing!
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
RT @BenediktSchrage: Two landmark RCTs, MADIT II and SCD-HeFT, have established the concept of ICDs for the primary prevention of SCD in pa…
RT @BenediktSchrage: Two landmark RCTs, MADIT II and SCD-HeFT, have established the concept of ICDs for the primary prevention of SCD in pa…
This week, John Mandrola MD discusses suicidal ideation associated with GLP1 agonists, focusing on the implications for healthcare professionals. He also revisits the PARADIGM HF study and explores insights from recent…
This week's podcast discusses ICD generator changes, VT management, comorbidities in heart failure, and SGLT2 inhibitors after atrial fibrillation ablation, highlighting recent research and clinical insights for…
scd-heft試験 https://t.co/IlLGpXkTZF
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8F4lkH
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8F4lkH
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
RT @BenediktSchrage: Two landmark RCTs, MADIT II and SCD-HeFT, have established the concept of ICDs for the primary prevention of SCD in pa…
RT @BenediktSchrage: Two landmark RCTs, MADIT II and SCD-HeFT, have established the concept of ICDs for the primary prevention of SCD in pa…
Two landmark RCTs, MADIT II and SCD-HeFT, have established the concept of ICDs for the primary prevention of SCD in patients with HFrEF by showing a survival benefit with this approach. https://t.co/ZNRkekRxFR https://t.co/thHeU5OHn8 2/x
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
SCD-HeFT - 2005 - ICD vs amiodarone vs control in NYHA II/III and LVEF<35% - ↓mortality with ICD, ∅mortality with amiodarone - https://t.co/wk7J8FlWJh
@rntobsnteach @DrMarthaGulati @TheBJCA @DrRiyazPatel @MrTheProf @DrDavidWarriner @mmamas1973 @Perrycardium @chapdoc1 @drlynnemillar @bcostelloMD @DrChrisMcAloon @DeepDastidar @Dr_DanMD A great landmark trial published in 2005 paving the way for ICDs in severe LV dysfunction https://t.co/ToK4HzgZu2 - thanks for choosing!
(1/2)Trial of the day: SCD-HeFT Bardy GH, et al. "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure". The New England Journal of Medicine. 2005. 252(3):225-37. https://t.co/oGIBxYA2Th #FOAMcards